Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junping Shi

Showing results (101-110 of 178) with videos related to

Pageof 18
Sort By:
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 2, 2024
Morus alba L. (Sangzhi) alkaloids mitigate atherosclerosis by regulating M1/M2 macrophage polarizationDandan Peng, Fen Zhuge, Mingwei Wang, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|February 6, 2015
[A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver]Feng Shen, Ruidan Zheng, Yuqiang Mi, et al.
European Journal of Gastroenterology & Hepatology|April 10, 2025
Effect of high-intensity interval training on clinical parameters in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trialsJie Fu, Chunlan Liu, Luping Yang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 22, 2022
Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD)Li Shao, Jing Liu, Yu Song, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 5, 2023
Stimulation of Liver Fibrosis by N2 Neutrophils in Wilson's DiseaseXiaoxiao Mi, Yu Song, Chaohua Deng, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 30, 2022
ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 CellsHongli Yang, Fajuan Rui, Rui Li, et al.
Clinical Proteomics|May 13, 2025
Comprehensive analysis of chronic hepatitis B concurrent with non-alcoholic fatty liver disease: a proteomics report based on clinical liver samplesXin Tong, Yawen Wan, Shengxia Yin, et al.
Expert Review of Gastroenterology & Hepatology|January 23, 2023
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trialsYunpeng Gu, Lei Sun, Yining He, et al.
The Oncologist|February 12, 2020
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating MutationWei Zhang, Junping Shi, Rentao Li, et al.
BMC Gastroenterology|November 13, 2025
BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studiesZhenjie Zhuang, Fen Zhuge, Yinlan Liu, et al.
Pageof 18

Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 2, 2024
Morus alba L. (Sangzhi) alkaloids mitigate atherosclerosis by regulating M1/M2 macrophage polarizationDandan Peng, Fen Zhuge, Mingwei Wang, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|February 6, 2015
[A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver]Feng Shen, Ruidan Zheng, Yuqiang Mi, et al.
European Journal of Gastroenterology & Hepatology|April 10, 2025
Effect of high-intensity interval training on clinical parameters in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trialsJie Fu, Chunlan Liu, Luping Yang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 22, 2022
Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD)Li Shao, Jing Liu, Yu Song, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 5, 2023
Stimulation of Liver Fibrosis by N2 Neutrophils in Wilson's DiseaseXiaoxiao Mi, Yu Song, Chaohua Deng, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 30, 2022
ADAR1 Inhibits HBV DNA Replication via Regulating miR-122-5p in Palmitic Acid Treated HepG2.2.15 CellsHongli Yang, Fajuan Rui, Rui Li, et al.
Clinical Proteomics|May 13, 2025
Comprehensive analysis of chronic hepatitis B concurrent with non-alcoholic fatty liver disease: a proteomics report based on clinical liver samplesXin Tong, Yawen Wan, Shengxia Yin, et al.
Expert Review of Gastroenterology & Hepatology|January 23, 2023
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trialsYunpeng Gu, Lei Sun, Yining He, et al.
The Oncologist|February 12, 2020
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating MutationWei Zhang, Junping Shi, Rentao Li, et al.
BMC Gastroenterology|November 13, 2025
BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studiesZhenjie Zhuang, Fen Zhuge, Yinlan Liu, et al.
Pageof 18